>アジア太平洋地域の神経内分泌腫瘍市場、分類別（機能性腫瘍と非機能性腫瘍）、部位別（肺、膵臓、消化管（GI）、グレード別（グレード1 {低悪性度腫瘍}、グレード2 {中悪性度腫瘍}、グレード3 {高悪性度腫瘍}）、タイプ別（診断と治療）、投与経路別（経口および非経口）、購入方法別（処方箋および市販薬（OTC））、エンドユーザー別（病院、専門クリニック、放射線センター、在宅医療など）、流通チャネル別（直接入札、病院薬局、小売薬局、オンライン薬局など）、国別（中国、日本、インド、オーストラリア、韓国、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、その他のアジア太平洋地域）2028年までの業界動向と予測
市場分析と洞察：アジア太平洋地域の神経内分泌腫瘍市場
神経内分泌腫瘍市場は、2021年から2028年の予測期間に市場成長を遂げると予想されています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に11.5％のCAGRで成長し、2028年までに9億2,949万米ドルに達すると分析しています。市場プレーヤーによる戦略的イニシアチブと神経内分泌腫瘍の集団ワクチン接種プログラムの出現は、予測期間における市場の需要を推進する主な原動力となる可能性があります。
腫瘍の発生は、健康な細胞の DNA が損傷を受けたときに起こり、その結果、細胞が制御不能な形で変化し、増殖し、細胞の凝集塊を形成します。腫瘍には、癌性と良性があります。悪性の癌性腫瘍は、早期に発見され治療されなければ、増殖して体の他の部位に広がります。良性腫瘍は増殖しますが、広がることはありません。良性腫瘍は通常、低侵襲手術を使用して、大きな害を与えることなく除去できます。神経内分泌腫瘍 (NET) は、体の神経内分泌系の特殊な細胞で発生します。これらの細胞は、ホルモン産生内分泌細胞と神経細胞の両方の共通の特徴を備えています。これらは体の臓器全体に見られ、体の多くの機能を制御する役割を担っています。すべての NET は悪性腫瘍とみなされます。NET のほとんどは、発生してゆっくりと増殖するのに何年もかかります。
しかし、治療に伴う副作用、いくつかの地域で満たされていないニーズと医療資源へのアクセス、診断の高コストなどの要因が、神経内分泌腫瘍市場の成長を妨げています。一方、今後の標的治療と市場プレーヤー間のパートナーシップとコラボレーションの増加は、神経内分泌腫瘍市場の成長の機会として機能します。償還ポリシーの欠如と神経内分泌腫瘍薬の開発に対する厳格な政府規制は、神経内分泌腫瘍市場が直面している課題です。
神経内分泌腫瘍市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、希望する目標を達成するための収益影響ソリューションの作成をお手伝いします。
神経内分泌腫瘍の市場範囲と市場規模
神経内分泌腫瘍市場は、分類、部位、グレード、タイプ、投与経路、エンドユーザー、流通チャネルに基づいてセグメント化されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
- 分類に基づいて、神経内分泌腫瘍市場は機能的ネットと非機能的ネットに分類されます。2021年には、識別と診断の容易さと、非機能的ネットを除去するための新しい診断方法の使用により、非機能的ネットセグメントが神経内分泌腫瘍市場を支配しています。
- 神経内分泌腫瘍市場は、部位別に肺、膵臓、消化管（GI）に区分されています。2021年には、胃がんの罹患率の増加と強力な製品パイプラインの存在により、神経内分泌腫瘍市場では消化管（GI）セグメントが優勢となり、市場を支配すると予測されています。
- 神経内分泌腫瘍市場は、グレードに基づいてグレード1（低グレード腫瘍）、グレード2（中グレード腫瘍）、グレード3（高グレード腫瘍）に分類されます。2021年には、グレード2（中グレード腫瘍）セグメントが神経内分泌腫瘍市場を支配しており、これは治療によって容易に治癒できるためであり、グレード2（中グレード腫瘍）症例の増加が市場を支配すると予測されています。
- タイプに基づいて、神経内分泌腫瘍市場は診断と治療に分割されます。2021年には、膵臓癌の発生率の増加と市場での自動化されたポイントオブケア診断の採用の増加により、診断セグメントが神経内分泌腫瘍市場を支配すると予想されます。
- 投与経路に基づいて、神経内分泌腫瘍市場は経口と非経口に分類されます。2021年には、経口剤の入手可能性、患者のコンプライアンスの向上、吸収の容易さにより、経口セグメントが神経内分泌腫瘍市場を支配すると予想されます。
- エンドユーザーに基づいて、神経内分泌腫瘍市場は、病院、専門クリニック、放射線センター、在宅医療などに分割されています。2021年には、医療政策の利用可能性とともに神経内分泌腫瘍を検出するための診断機器の利用可能性により、病院セグメントが神経内分泌腫瘍市場を支配すると予想されます。
- 流通チャネルに基づいて、神経内分泌腫瘍市場は、直接入札、病院薬局、小売薬局、オンライン薬局などに分類されます。 2021年には、市場におけるサプライヤーの増加により、直接入札セグメントが神経内分泌腫瘍市場を支配すると予想されます。
神経内分泌腫瘍市場の 国別分析
神経内分泌腫瘍市場が分析され、上記の分類、部位、グレード、タイプ、投与経路、エンドユーザー、流通チャネルに基づいて市場規模の情報が提供されます。
神経内分泌腫瘍市場レポートで取り上げられている国は、中国、日本、インド、オーストラリア、韓国、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、その他のアジア太平洋諸国です。
アジア太平洋地域は、予測期間中に最も高い CAGR で成長すると予想されています。都市化と実験室の自動化により神経内分泌腫瘍製品の需要が急速に増加しているため、中国が市場を独占すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
政府の取り組みの増加と市場プレーヤーによる協力の増加により、神経内分泌腫瘍市場に新たな機会が生まれています。
神経内分泌腫瘍市場では、神経内分泌腫瘍の売上を伴う特定の産業における各国の成長、神経内分泌腫瘍の進歩の影響、神経内分泌腫瘍市場への支援を伴う規制シナリオの変化に関する詳細な市場分析も提供されます。データは、2010 年から 2019 年までの履歴期間について利用可能です。
競争環境と神経内分泌腫瘍の市場シェア分析
神経内分泌腫瘍市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、神経内分泌腫瘍市場に関連する会社の焦点にのみ関連しています。
神経内分泌腫瘍市場の主要企業には、Novartis AG、Ipsen Pharma、Viatris Inc.、Callisto Pharmaceuticals、Eli Lilly and Company、Bristol-Myers Squibb Company、Pfizer Inc.、GlaxoSmithKline plc、Thermo Fisher Scientific Inc.、Hutchison China MediTech Limited、F. Hoffmann-La Roche Ltd、Bionano Genomics、Teva Pharmaceutical Industries Ltd.、Merck Sharp & Dohme Corp.（Merck & Co., Inc.の子会社）、Sun Pharmaceutical Industries Ltd.、Illumina, Inc.、LUPINなど、世界的または国内の企業が挙げられます。DBMRアナリストは、競争力を理解し、各競合他社の競合分析を個別に提供します。
世界中の企業によって多くの製品の発売や契約も開始されており、神経内分泌腫瘍市場の成長を加速させています。
例えば、
- ノバルティスAGは2018年1月、同社の子会社であるAdvanced Accelerator Applicationsが、成人の前腸、中腸、後腸神経内分泌腫瘍を含むソマトスタチン受容体陽性の膵消化管神経内分泌腫瘍（GEP-NET）の治療薬として、新薬申請Lutathera（ルテチウムLu 177ドタテート*）のFDA承認を取得したと発表しました。同社が取得したFDA承認により、臨床試験が増加し、神経学における腫瘍学製品ポートフォリオが強化され、市場のプラス成長がもたらされるでしょう。
市場プレーヤーによるコラボレーション、ジョイントベンチャー、その他の戦略により、神経内分泌腫瘍市場における企業市場が強化され、組織が治療の提供を改善するメリットももたらされます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASSIFICATION LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 PRICING ANALYSIS
7 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: REGULATIONS
7.1 REGULATORY PROCEDURE IN THE U.S.
7.2 REGULATORY PROCEDURE IN CANADA
7.3 REGULATORY PROCEDURE IN EUROPE
7.4 REGULATORY PROCEDURE IN CHINA
7.5 REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA
8 COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY
8.1 MONOCLONAL ANTIBODY
8.2 POLYCLONAL ANTIBODY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASED INCIDENCE OF NEUROENDOCRINE TUMOR CASES
9.1.2 TECHNOLOGICAL ADVANCEMENT FOR THE DETECTION OF NEUROENDOCRINE TUMORS
9.1.3 GROWTH IN THE NUMBER OF PRIVATE DIAGNOSTIC CENTERS AND TREATMENT PROVIDERS
9.1.4 PRESENCE OF TARGETED TREATMENT OPTIONS
9.1.5 FAVORABLE REIMBURSEMENT POLICIES
9.2 RESTRAINTS
9.2.1 HIGH CAPITAL INVESTMENTS & LOW BENEFIT-COST RATIO FOR BIOMARKERS AND ORPHAN DRUGS
9.2.2 LACK OF AWARENESS AMONG THE POPULATION
9.2.3 UNMET NEEDS AND ACCESS TO MEDICAL RESOURCES IN SEVERAL REGIONS
9.2.4 HIGH COST OF DIAGNOSIS
9.3 OPPORTUNITIES
9.3.1 INCREASED GOVERNMENT INITIATIVES
9.3.2 EMERGING THERAPIES & DEVELOPMENT IN TREATMENT
9.3.3 RISING COLLABORATIONS AMONG THE MARKET PLAYERS
9.4 CHALLENGES
9.4.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS
9.4.2 STRINGENT GOVERNMENT REGULATIONS FOR THE DEVELOPMENT OF NEUROENDOCRINE TUMOR DRUGS
10 IMPACT OF COVID 19 ON ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET
10.1 PRICE IMPACT
10.2 IMPACT OF DEMAND
10.3 IMPACT ON SUPPLY CHAIN:
10.4 STRATEGIC DECISIONS:
10.5 CONCLUSION:
11 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION
11.1 OVERVIEW
11.2 NON-FUNCTIONAL NET
11.3 FUNTIONAL NET
12 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE
12.1 OVERVIEW
12.2 GASTROINTESTINAL TRACT (GI)
12.3 LUNGS
12.4 PANCREAS
13 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE
13.1 OVERVIEW
13.2 GRADE 2 (INTERMEDIATE-GRADE TUMOR)
13.3 GRADE 3 (HIGH-GRADE TUMOR)
13.4 GRADE 1( LOW-GRADE TUMOR)
14 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE
14.1 OVERVIEW
14.2 DIAGNOSIS
14.2.1 BLOOD TEST
14.2.2 IMAGING TEST
14.2.2.1 CTSCAN
14.2.2.2 MRI
14.2.2.3 OTHERS
14.2.3 BIOPSY
14.2.4 URINE TEST
14.2.5 OTHERS
14.3 TREATMENT
14.3.1 SOMATOSTATIN ANALOGS
14.3.1.1 OCTREOTIDE
14.3.1.2 LANREOTIDE
14.3.2 TARGETED THERAPY
14.3.2.1 EVEROLIMUS
14.3.2.2 SUNITINIB
14.3.2.3 OTHERS
14.3.3 RADIATION THERAPY
14.3.3.1 EXTERNAL-BEAM RADIATION
14.3.3.2 INTERNAL-BEAM RADIATION
14.3.4 SURGERY
14.3.4.1 CHOLECYSTECTOMY
14.3.4.2 OTHERS
14.3.5 LIVER-DIRECTED TREATMENT
14.3.5.1 RADIO FREQUENCY ABLATION (RFA)
14.3.5.2 HEPATIC ARTERY EMBOLIZATION
14.3.5.3 RADIOEMBOLIZATION
14.3.6 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)/ LUTATHERA
15 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLETS
15.2.2 PILLS
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 SUBCUTANEOUS
15.3.2 INTRAMUSCULAR
15.3.3 OTHERS
16 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALITY CLINICS
16.4 RADIATION CENTERS
16.5 HOME HEALTHCARE
16.6 OTHERS
17 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL SALES
17.5 ONLINE PHARMACY
17.6 OTHERS
18 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GEOGRAPHY
18.1 ASIA PACIFIC
18.1.1 CHINA
18.1.2 JAPAN
18.1.3 INDIA
18.1.4 AUSTRALIA
18.1.5 MALAYSIA
18.1.6 INDONESIA
18.1.7 SOUTH KOREA
18.1.8 SINGAPORE
18.1.9 PHILIPPINESS
18.1.10 THAILAND
18.1.11 VIETNAM
18.1.12 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20 SWOT
21 COMPANY PROFILES
21.1 F. HOFFMANN-LA ROCHE LTD
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 BRISTOL-MYERS SQUIBB COMPANY
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 VIATRIS INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 COMPANY SHARE ANALYSIS
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENTS
21.4 THERMO FISHER SCIENTIFIC INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 NOVARTIS AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 REGENERON PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 BIONANO GENOMICS
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENTS
21.9 BIOSYNTHEMA INC.
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENTS
21.1 CALLISTOPHARMA
21.10.1 COMPANY SNAPSHOT
21.10.2 PRODUCT PORTFOLIO
21.10.3 RECENT DEVELOPMENTS
21.11 ELI LILLY AND COMPANY
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENTS
21.12 EXACT SCIENCES CORPORATION
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENTS
21.13 GLAXOSMITHKLINE PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENTS
21.14 HUTCHISON CHINA MEDITECH LIMITED
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 IPSEN PHARMA
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 ILLUMINA, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 LUPIN
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENTS
21.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 PFIZER INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENTS
21.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
表のリスト
TABLE 1 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, PIPELINE ANALYSIS
TABLE 2 SALES DATA OF ONCOLOGY MARKET FOR 2019/2020
TABLE 3 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028(USD MILLION)
TABLE 4 ASIA-PACIFIC NON-FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 5 ASIA-PACIFIC FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 6 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC GASTROINTESTINAL TRACT (GI) IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC LUNGS IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC PANCREAS NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC GRADE 2 (INTERMEDIATE-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC GRADE 3 (HIGH-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC TREATMENT NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC LIVER-DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC HOSPITALS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC SPECIALITY CLINICS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC RADIATION CENTERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC OTHERS IN RADIOTHERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC DIRECT TENDER IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HOSPITAL PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC RETAIL SALES IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC ONLINE PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 44 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 45 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 46 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 47 ASIA PACIFICDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 48 ASIA PACIFICIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 49 ASIA PACIFICTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 50 ASIA PACIFICSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 51 ASIA PACIFICTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 52 ASIA PACIFICRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 53 ASIA PACIFICSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 54 ASIA PACIFICLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 55 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 56 ASIA PACIFICORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 57 ASIA PACIFICPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 58 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 59 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 60 CHINANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 61 CHINANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 62 CHINANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 63 CHINANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 64 CHINADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 65 CHINAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 66 CHINATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 67 CHINASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 68 CHINATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 69 CHINARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 70 CHINASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 71 CHINALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 72 CHINANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 73 CHINAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 74 CHINAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 75 CHINANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 76 CHINA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 77 JAPANNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 78 JAPANNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 79 JAPANNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 80 JAPANNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 81 JAPANDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 82 JAPANIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 83 JAPANTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 84 JAPANSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 85 JAPANTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 86 JAPANRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 87 JAPANSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 88 JAPANLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 89 JAPANNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 90 JAPANORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 91 JAPANPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 92 JAPANNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 93 JAPAN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 94 INDIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 95 INDIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 96 INDIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 97 INDIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 98 INDIADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 99 INDIAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 100 INDIATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 101 INDIASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 102 INDIATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 103 INDIARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 104 INDIASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 105 INDIALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 106 INDIANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 107 INDIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 108 INDIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 109 INDIANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 110 INDIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 111 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 112 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 113 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 114 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 115 AUSTRALIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 116 AUSTRALIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 117 AUSTRALIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 118 AUSTRALIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 119 AUSTRALIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 120 AUSTRALIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 121 AUSTRALIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 122 AUSTRALIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 123 AUSTRALIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 124 AUSTRALIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 125 AUSTRALIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 126 AUSTRALIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 127 AUSTRALIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 128 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 129 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 130 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 131 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 132 MALAYSIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 133 MALAYSIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 134 MALAYSIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 135 MALAYSIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 136 MALAYSIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 137 MALAYSIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 138 MALAYSIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 139 MALAYSIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 140 MALAYSIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 141 MALAYSIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 142 MALAYSIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 143 MALAYSIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 144 MALAYSIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 145 INDONESIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 146 INDONESIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 147 INDONESIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 148 INDONESIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 INDONESIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 150 INDONESIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 151 INDONESIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 152 INDONESIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 153 INDONESIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 154 INDONESIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 155 INDONESIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 INDONESIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 INDONESIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 158 INDONESIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 159 INDONESIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 160 INDONESIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 161 INDONESIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 162 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 163 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 164 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 165 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 166 SOUTH KOREA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 167 SOUTH KOREA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 168 SOUTH KOREA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 169 SOUTH KOREA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 170 SOUTH KOREA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 171 SOUTH KOREA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 172 SOUTH KOREA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 173 SOUTH KOREA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 174 SOUTH KOREAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 175 SOUTH KOREAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 176 SOUTH KOREAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 177 SOUTH KOREAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 178 SOUTH KOREA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 179 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 180 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 181 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 182 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 183 SINGAPORE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 184 SINGAPORE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 185 SINGAPORE TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 186 SINGAPORE SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 187 SINGAPORE TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 188 SINGAPORE RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 189 SINGAPORE SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 190 SINGAPORE LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 191 SINGAPOREEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 192 SINGAPOREORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 193 SINGAPOREPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 194 SINGAPOREEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 195 SINGAPORE NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 196 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 197 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 198 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 199 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 200 PHILIPPINESS DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 201 PHILIPPINESS IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 202 PHILIPPINESS TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 203 PHILIPPINESS SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 204 PHILIPPINESS TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 205 PHILIPPINESS RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 206 PHILIPPINESS SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 207 PHILIPPINESS LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 208 PHILIPPINESSEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 209 PHILIPPINESSORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 210 PHILIPPINESSPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 211 PHILIPPINESSEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 212 PHILIPPINESS NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 213 THAILAND NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 214 THAILANDNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 215 THAILANDNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 216 THAILANDNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 217 THAILAND DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 218 THAILAND IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 219 THAILAND TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 220 THAILAND SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 221 THAILAND TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 222 THAILAND RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 223 THAILAND SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 224 THAILAND LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 225 THAILANDEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 226 THAILANDORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 227 THAILANDPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 228 THAILANDEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 229 THAILAND NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 230 VIETNAM NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 231 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 232 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 233 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 234 VIETNAM DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 235 VIETNAM IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 236 VIETNAM TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 237 VIETNAM SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 238 VIETNAM TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 239 VIETNAM RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 240 VIETNAM SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 241 VIETNAM LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 242 VIETNAMEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 243 VIETNAMORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 244 VIETNAMPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 245 VIETNAMEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 246 VIETNAM NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 247 REST OF ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
図表一覧
FIGURE 1 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: ASIA-PACIFIC VS REGIONAL ANALYSIS
FIGURE 5 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 11 INCREASED AWARENESS OF NEUROENDOCRINE TUMORS CASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 NON-FUNTIONAL NET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET IN 2021 & 2028
FIGURE 13 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016
FIGURE 14 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S.
FIGURE 15 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, 2020
FIGURE 16 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2020-2028 (USD MILLION)
FIGURE 17 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, CAGR (2021-2028)
FIGURE 18 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, 2020
FIGURE 20 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE, 2020-2028 (USD MILLION)
FIGURE 21 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, CAGR (2021-2028)
FIGURE 22 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, 2020
FIGURE 24 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2020-2028 (USD MILLION)
FIGURE 25 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, CAGR (2021-2028)
FIGURE 26 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, 2020
FIGURE 28 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2020-2028 (USD MILLION)
FIGURE 29 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 30 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINSTRATION, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, 2020
FIGURE 36 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER, 2020-2028 (USD MILLION)
FIGURE 37 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 41 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020)
FIGURE 44 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020)
FIGURE 45 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY STRAINS (2021-2028)
FIGURE 48 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
